Population modification of Anopheline species to control malaria transmission

Rebeca Carballar-Lejarazú & Anthony A. James

To cite this article: Rebeca Carballar-Lejarazú & Anthony A. James (2018): Population modification of Anopheline species to control malaria transmission, Pathogens and Global Health, DOI: 10.1080/20477724.2018.1427192

To link to this article: https://doi.org/10.1080/20477724.2018.1427192
Population modification of Anopheline species to control malaria transmission

Rebeca Carballar-Lejarazu and Anthony A. James

Department of Microbiology & Molecular Genetics, University of California, Irvine, CA, USA; Department of Molecular Biology & Biochemistry, University of California, Irvine, CA, USA

ABSTRACT

Vector control strategies based on population modification of Anopheline mosquitoes may have a significant role in the malaria eradication agenda. They could consolidate elimination gains by providing barriers to the reintroduction of parasites and competent vectors, and allow resources to be allocated to new control sites while maintaining treated areas free of malaria. Synthetic biological approaches are being used to generate transgenic mosquitoes for population modification. Proofs-of-principle exist for mosquito transgenesis, the construction of anti-parasite effector genes and gene-drive systems for rapidly introgressing beneficial genes into wild populations. Key challenges now are to develop field-ready strains of mosquitoes that incorporate features that maximize safety and efficacy, and specify pathways from discovery to development. We propose three pathways and a framework for target product profiles that maximize safety and efficacy while meeting the demands of the complexity of malaria transmission, and the regulatory and social diversity of potential end-users and stakeholders.

Introduction

Human disease and deaths resulting from malaria have decreased significantly over the last two decades fueling the enthusiasm for pursuing the goal of malaria eradication [1]. These reductions have been achieved mostly through the increased availability of effective therapeutic drug combinations and insecticide-treated bed nets and indoor spraying [2]. However, there are still over 400 thousand deaths every year, and modeling predicts that the downward trend will reverse with the failure of existing technologies and the absence of new disease-control tools [3].

Vector biologists have proposed a variety of new approaches to contribute to reducing parasite transmission and some are actively pursuing genetic strategies that could impact mosquito populations [3]. These approaches seek either to eliminate or reduce vector mosquito populations below thresholds needed for stable parasite transmission (population suppression), or make them incapable of transmitting pathogens (population replacement/modification) [4]. Proofs-of-principle for both approaches have been demonstrated and efforts are underway to move the advances from the laboratory to the field. A case was made recently for the value of population modification in the eradication agenda and this was based on the demonstrated need for technologies that could provide long-term, cost-effective and sustainable regional malaria elimination [5].

Recent modeling provides additional support for the potential impact of the approaches [6,7]. We complement these reports by reviewing briefly the concept of population modification and posing questions about the challenges of the next steps. A critical task is to specify pathways for further development of the technologies and to define the specific products to be used in population modification control programs.

What is population modification?

Core concepts of population modification for vector-borne disease control were first aggregated in a single paragraph by Christopher Curtis in which he stated: “Mutant genes can be imagined the presence of which in a population would be favorable to man, without being very deleterious to the insect. As an example, genes will be considered of a type already known, which make mosquitoes non-infectible by pathogens…. At fixation, the population would be harmless to man…. This type of procedure may be preferable to methods which eradicate a pest species in an area, leaving its ecological niche vacant for reinfestation by immigrants.” [8]

The publication was addressing the theoretical use of chromosome translocations to introgress ‘mutant genes’ into wild mosquito populations, so while defining anti-parasite effector genes, Curtis was at the same time proposing a mechanism to achieve gene drive. We recognize the translocation system as a variant of what
As the program proceeds, population modification is predicted in models to take on a larger role in the prevention-of-reintroduction phase [5,6]. Parasite-resistant mosquitoes would facilitate consolidation of elimination and allow resources to be allocated to another target region with the confidence that the malaria-free area will remain so. Furthermore, as Curtis proposed, unlike population suppression, population modification is expected to provide a level of environmental safety because it would not result in an ‘empty’ ecological niche that could be occupied by an opportunistic invasive species that may have an expanded vector competence and vectorial capacity. (Vector competence is defined as the intrinsic ability of the insect to transmit a pathogen and includes genetic components [13]. Vectorial capacity is an expression of the efficiency of parasite transmission, and recent formulations include vector competence as a parameter [14]). In addition, modeling supports the conclusion that modification approaches should be stable in low mosquito population densities [6]. This is important in regions where mosquito population sizes fluctuate annually during wet and dry seasons. Similarly, population modification schemes are robust to locally-isolated wild populations since the modified population surrounding a pocket of unmodified mosquitoes will persist until the modified mosquitoes eventually gain access to it. In contrast, population suppression schemes can bypass such disease-bearing populations and then vanish rapidly from the local environment resulting in repopulation of the region with the original unmodified, disease-competent mosquitoes.

What are the benefits of population modification?

Population modification programs alone are not likely to eradicate malaria; this will be achieved using the full array of tools that eliminate parasites in humans (prophylactic and therapeutic drugs, vaccines [when available]) and those targeting the vector (source reduction, insecticides, spatial repellants, and others). However, population modification is expected to provide sustainability to the WHO-defined control, pre-elimination, elimination and prevention-of-reintroduction phases of local malaria elimination [5,6]. This sustainability feature is important because it is the basis for claims that population modification is expected to provide a cost-effective means of preserving local elimination. Population modification strains can serve as barriers to the reinvansion of wild, parasite-susceptible mosquitoes as any insect of the same species introduced into the treated area will acquire parasite-resistance genes through breeding with the local-introduced pathogen-resistant insects, and immigrating parasite-infected people will not be able to infect the resident vectors, and therefore not be a source of parasites for infection of other people in that region.

Population modification also shares with other genetic control strategies the ability of male mosquitoes to find females, and this should facilitate access to vector populations that are unreachable using conventional tools [12]. Population modification strategies can be used in the control phase of an elimination campaign alongside other measures to reduce disease incidence.
to be some of the best. Finally, and importantly, transgenesis technologies based on transposable elements were developed that allowed the stable and heritable introduction of engineered genes into Anopheline mosquitoes [17,18]. These combined advances made it possible to demonstrate the proof-of-principle that molecular genetic techniques could be used to make mosquitoes that are incapable of transmitting human malaria parasites [19,20].

The next major challenge was to develop a technology to move synthetic anti-parasite genes into wild populations of mosquitoes in an epidemiologically-relevant time frame [21,22]. Most researchers favor some type of ‘gene-drive’ approach that would rapidly introgress genes by subverting normal patterns of Mendelian inheritance, and the adaption of CRISPR/Cas9 biology, a variation of a homing endonuclease strategy, has great promise (Figure 2) [23–25]. Indeed, this approach comes with such high expectations that a flurry of research community and agency evaluations and commentaries seek to make sure that regulatory regimes and public understanding of the technology can keep pace with the scientific developments [10,26–28]. Alternately, it was shown in laboratory cage trials that releases of population modification strains lacking active drive systems, but expressing mosquito immune system genes altered the midgut microbiome and enhanced transgene spread [29]. This phenomenon could have a positive additive effect on the rate at which these specific constructs introgress into wild populations.

### Table 1. Antimalarial effector genes and targets.

| Effector class       | Molecule               | Target parasite          | Reference |
|----------------------|------------------------|--------------------------|-----------|
| Parasite ligands     | Pbs21 scFv             | *Plasmodium berghei*     | [49]      |
|                      | N2 scFv (targets CSP)  | *Plasmodium falciparum*  | [50]      |
|                      | scFv 487 (targets Pf525)| *Plasmodium falciparum*  | [51]      |
|                      | scFv 1C3 (targets parasite chitinase) | *P. falciparum* | [51] |
|                      | scFv 2A10 (targets CSP) | *P. falciparum*          | [51]      |
|                      | Pbs21 scFv plus Shiva 1 | *P. berghei*             | [52]      |
| Tissue recognition   | PINPNA-1               | *P. gallinaceum*         | [53]      |
| (receptors)          | Lectins, Mabs          | *P. berghei*             | [54]      |
|                      | SM1 peptide            | *P. gallinaceum, P.berghei* | [55] |
| Immune response      | Snake phospholipase A2 | *P. falciparum, P.berghei* | [56] |
| effectors (parasite killing) | Bee phospholipase A2 | *P. berghei*             | [57]      |
|                      | Chitinase               | *P. gallinaceum*         | [58]      |
|                      | Magaminins and/or cecropins | Various Plasmodium spp. | [59] |
|                      | Defensins               | *P. gallinaceum*         | [60]      |
|                      | Gambicin                | *P. berghei*             | [61]      |
|                      | Gomesin                 | *P. berghei*             | [62]      |
|                      | Shiva                   | *P. berghei*             | [63]      |
|                      | NOS                     | *P. berghei*             | [64]      |
|                      | CEL-III                 | *P. falciparum, P.berghei* | [65] |
|                      | TP10                    | *P. falciparum*          | [66]      |
|                      | AdDLP                   | *P. berghei*             | [67]      |
|                      | Meucin-25               | *P. falciparum, P.berghei* | [68] |
| Antiparasite toxins  | Scorpion                | *P. berghei, P. falciparum* | [69,70] |
| Others               | FREP                    | Various Plasmodium spp.  | [71]      |
|                      | Akt                     | *P. falciparum, P.berghei* | [19] |
|                      | Re12                    | *P. falciparum, P.berghei* | [72] |

**Abbreviations:** AdDLP, Anaeromyxobacter dehalogenans defensin-like peptide; Akt, protein kinase B; CEL-III, Cucumaria echinata lectin III; CSP, circumsporozoite protein; FREP, fibrinogen-related protein; Mabs, monoclonal antibodies; NOS, nitric oxide synthase; NPNA, repetitive epitope An-Prot-Anti-A; Pf(s), Plasmodium berghei (surface); Pf(s), Plasmodium falciparum (surface); Rel, Relish; SM1, salivary gland and midgut peptide 1; scFv, single-chain antibodies; TP, transportan.

### Table 2. Anopheline mosquito cis-acting DNA elements for expressing effector molecules.

| Compartments       | Gene origin          | Expression   | Reference |
|--------------------|----------------------|--------------|-----------|
| Midgut             | Peritrophin          | Constitutive | [73]      |
|                    | Carboxypeptidase     | Inducible    | [74]      |
|                    | Trypsin              | Inducible    | [74]      |
|                    | G12                  | Inducible    | [74]      |
| Hemolymph          | Vitellogenin         | Inducible    | [75]      |
| Salivary glands    | Anopheline anti-platelet protein (AAPP) | Constitutive | [76] |
|                    | Apyrase              | Constitutive | [77]      |

Figure 1. Synthetic approach to making anti-parasite effector genes. A synthetic approach to making an anti-parasite effector gene starts with a simple model of a gene (A) comprising two parts. The control region contains cis-acting DNA that regulates when during development, where in the vector insect, and how much of a product is made. Constitutive and regulated endogenous mosquito genes with sex-, stage- and tissue-specific expression profiles have been used for the control regions (Table 2). The effector region is the expressed portion of the gene that kills or disables the parasite. This may result from a direct action such as a single-chain antibody that binds the parasite or toxin that kills it, or an indirect action that deprives the parasite of an essential host factor, blocks an important ligand or elevates a systemic immune response (Table 1), (B) Control regions can be selected to deliver effector molecules to specific compartments (midgut, hemolymph, [open circulatory system]) and salivary glands in which specific parasite stages are found.

Notes: Malaria parasites enter the mosquito midgut (shaded red) as gametes following an infectious blood meal. Male and female gametes fuse to form zygotes that mature into motile ookinetes. Ookinetes penetrate the midgut epithelium and form an oocyst in which thousands of sporozoites develop. Sporozoites emerge from the oocyst and migrate through the hemolymph to the salivary glands (shaded yellow) prior to transmission to a new human host.
The final and critical challenge is to determine how the technologies can be applied in diverse malaria transmission settings. It is easy to appreciate that small, isolated communities in sub-Saharan Africa differ significantly from villages arrayed along the major rivers in South America, and that neither of these shares much ecologically or demographically with large cities in the Indian subcontinent. However, they all have either or both *Plasmodium falciparum* and *P. vivax* malaria and competent Anopheles vector species. Population modification approaches must be adapted to local conditions and therefore need to consider the biology of the mosquito species and target parasites in these areas. This is likely to be complicated in areas where multiple vector and parasite species contribute to the local malaria burden. Here combining the approach with other technologies, including genetic and conventional population suppression, could have a synergistic effect. In summary, we have excellent proofs-of-principle for generating anti-parasite transgenes and promising gene-drive systems, but much work needs to be done to adapt a population modification approach to a specific malaria transmission setting.

**What are possible pathways from discovery to development of population modification?**

A new technology matures through three stages, discovery, development and delivery, before it is accepted as an established practice (Figure 3). In the context used here, discovery starts with the conception of the idea and progresses through demonstrations of proof-of-principle. Development then investigates the practicality of the discovery to have a real-world impact and often involves scale-up parameters. Finally, delivery encompasses all that would be needed for implementation. Most of the discovery work researching population modification strategies has been done in laboratories in the developed world (designated here as 'discovery laboratories') with the intent to apply them in malaria transmission regions in disease-endemic countries (DECs). Several pathways can be imagined for moving the technology to development stages, and these vary in the nature of the product provided by discovery laboratories to end-users and stakeholders. The conceptual formulations and transgene designs of genetics-based population modification strategies and strains are part of the public literature and are accessible in large part to potential users. DECs with the scientific capabilities and public health and regulatory infrastructures (designated here as 'independent'), for example, some in Asia and Latin America, have the capacity now to use these formulations and designs to generate their own population modification strains that are relevant to their local mosquito species and parasites. From this perspective, the 'product' provided by discovery laboratories is the conceptual framework and is available already. There may be a need for discovery laboratories to contribute to training scientists as the independent DEC countries ramp up the technologies, but there is likely to be little demand for discovery laboratory scientists to be involved directly in the deployment of the approaches. Independent DECs also will have the capacity to submit the products for regulatory review, garner community support and raise funds for trials. They will be able to conduct in-country trials and follow through with delivery should the products meet performance criteria and gain regulatory and community approval.
In contrast, DECs lacking some components of the scientific expertise may work more closely with discovery laboratories to adapt population-modification technologies to their local situation. We will discuss two such pathways, one in which the discovery laboratories provide a DNA construct capable of gene drive and conferring a malaria resistance phenotype to a specific Anopheline species mosquito (‘DNA only’; Figure 3), and one in which the discovery laboratories provide the actual genetically-engineered strains for field testing (‘DNA and strain’).

All three of the pathways likely will adhere to a phase-based testing regimen for the technologies, and the vector biology community and we endorse this approach [11,27]. The WHO recognizes four phases: Phase 1 tests comprise the discovery stages and are physically-confined studies in laboratories and insectaries; Phase 2 trials move the products to development and are carried out in small-scale physically and/or ecologically contained field tests; Phase 3 continues development in a series of open release trials that increase in size, length and complexity at one or more sites; and Phase 4 moves the technology to wider application as a malaria control tool in the delivery stage. Specific products are evaluated and subjected to rigorous ‘go/no go’ criteria in each phase. Each step also is accompanied by a phase-specific regulatory structure and includes community engagement and communication activities [5]. These Phases are being reviewed and revised now because of recent successes of gene-drive components.

It is essential that the first field trial of population modification technologies be a success [5]. Funding agencies are unlikely to continue to support the development phases if the first effort ends in failure. Towards that end, site-selection criteria have been proposed to maximize the probability of a positive outcome [30]. Follow-up trials will evaluate product performance in regions with variable levels of parasite transmission, different vector species and seasonal variations in population sizes [11].

**What are the population modification products and how good do they have to be?**

While the pathways for further development of population modification approaches may be different for specific DEC countries, there is a clear need for all to define specifically what the final products will be. Furthermore, while we can describe the properties of a perfect population modification product, practical applications require that we determine just how good it must be to be useful. Efforts are now underway to develop Target Product Profiles (TPP) for these genetic technologies. TPPs are used widely in other product-driven disciplines to provide the basis for evaluation of whether a product should be made available for use.

At their most basic level, TPPs have three components, (1) a list of key parameters of the product, (2) a description of each of these features in their perfect form (ideal characteristics), and importantly, (3) a parallel list of how good each feature must be for the product to have practical value (minimally essential). While the ideal characteristics can be formulated by providing what would be the perfect outcome, minimally essential features should be based on empirical studies, or in their absence, rigorous modeling. Population modification TPPs will need to meet efficacy and safety standards and the demands of the different regulatory and cultural contexts in which the products will be used. TPPs also should consider adverse effects and inform product design efforts to mitigate undesired outcomes. Independent DECs likely will develop their own TPPs, but others may work with the discovery laboratories to fashion theirs.
A model of a DNA construct-specific TPP
A strong argument for DNA constructs being the products delivered by discovery laboratories is that this approach engages and empowers DEC scientists and stakeholders early in product development, and facilitates the introduction of constructs into local trial-site mosquito species and populations. All phase trials would be conducted by DEC scientists and supervised by in-country authorities. In addition, international regulatory procedures are more favorable for shipping DNA plasmids to a potential trial country than live genetically-engineered strains. Furthermore, the logistics of shipment are expected to be less expensive. This pathway requires that the DEC scientists have the capability to create transgenic mosquitoes. It is crucial that the discovery laboratories contribute to capacity building by training of these scientists in these technologies.

Key parameters of a population modification DNA construct include those that address its fundamental architecture, the anti-parasite effector genes and the autonomous gene-drive system (Table 3). The source DNA parameter could address both scientific and social criteria. Ideally, DNA derived only from the target mosquito would insure that the transgenes function well in the context of the specific species and mitigate concerns about the introduction of ‘foreign’ DNA into a species. However, many components of the final construct may be exogenous and have no corresponding endogenous equivalent. For example, several anti-effector molecules originate in bacteria or vertebrates, or are completely synthetic. While codon-biases can be manipulated to increase expression properties and make them appear more ‘mosquito-like’ to the insect host expression machinery, they are not truly mosquito genes [20]. Furthermore, the elements of CRISPR/Cas9-based gene-drive systems are derived from bacteria and produced synthetically, and the fluorescent marker genes also are exogenous [24,25]. Therefore, it is minimally essential that the source DNA, including the control DNA sequences for expressing the various components, is functional and stable within the target species.

Stability of the construct refers to the molecular integrity of the DNA conferring the parasite-resistance and drive capabilities. While ideally, there would be no loss of function associated with mutations of the component genes or genomic target sites, or loss through uncoupling by recombination of the drive mechanism from the effector genes, the construct need only last long enough to contribute to maintaining local malaria elimination [6,7]. Basic engineering principles dictate that the smaller and less complex a system is, the less likely it is to fail; however, this may not translate well to biological systems, which can be redundant. Some redundancy may be necessary (for example, multiplexing guide RNAs [gRNAs] and target sites for the gene drive machinery) [31], but it would be good to have the minimally-essential criteria strive to keep the construct as simple as possible to decrease the probability of random mutations while ensuring that it is functionally stable. Simple constructs also are less likely to give rise to unforeseen failures.

The ideal design characteristics of an anti-parasite effector molecule would be that it could disable all worldwide populations of human malaria parasites. This would result from effector molecule targets that are functionally, and possibly structurally, conserved across parasite species so that a single molecular configuration would have the same effect on all of them. While the search for these is on-going, it should be minimally acceptable to have effector molecule(s) that work regionally to disable either P. falciparum or P. vivax as this would have the greatest impact on morbidity and mortality.

Work that developed single-chain antibodies as effector molecules showed that single copies of two transgenes (‘dual-approach’) could prevent 100% of the sporozoites from entering the salivary glands at infection levels encountered in natural condition [20]. However, laboratory-induced infections resulted in intensities of

Table 3. Draft framework for a target product profile of transgene constructs: Partial list of key parameters and ideal and minimally essential performance features.

| Parameter                        | Ideal                                      | Minimally Essential                      |
|----------------------------------|--------------------------------------------|------------------------------------------|
| Source DNA Stability              | All orthologous from target species        | All control DNA functional and stable     |
|                                  | No breakdown due to mutation or recombination | Rate of breakdown does not preclude use in local elimination |
| Size Complexity                  | Small as possible for efficacy             | Same as ideal                            |
|                                  | Fewest components as possible to assure efficacy and safety | Same as ideal                            |
| Effector molecule species targeting | Kills or disables all human malaria parasites | Kills or disables either P. falciparum or P. vivax |
| Effector molecule efficacy       | Kills or disables global populations of human malaria parasites | Kills or disables regional populations of either P. falciparum and P. vivax |
| Effector molecule efficiency     | Highly conserved sequence in gene critical for parasite development, a mutation in which imposes no genetic load on the mosquito | Same as ideal |
| Drive target locus               |                                          | To be determined by target and load properties |
| Off-target drive effects         | No off-target effects                      | To be determined by target and load properties |
| Impact of resistant drive targets | No resistant targets                       | No impact on effector efficacy            |
| Non-target drive effects         | No non-target effects                      | Non-functional in other species          |
| Drive inheritance                | Both sexes                                 | One                                      |
infection (number of parasites per infected mosquito) much higher than those found in the field and some parasites escaped the effectors and infected the salivary glands. While this hyper-infection could be mitigated by providing additional bloodmeals that increased the levels of effector gene product, it would be prudent to avoid deploying effector genes that in principle might select for increased virulence manifest as higher mean intensities of infection in mosquitoes. This evolutionary route of parasite escape from the effectors could be blocked by adding additional genes to the construct, seeking improvements in the ones already tested, or potentially targeting host factors required for propagation of the pathogen.

The ideal target of the drive construct would be a location in the genome that is highly-conserved in its nucleotide sequence so as to have a low level of naturally-occurring alleles resistant to gRNA-directed cleavage, be in a locus that when mutated by the transgene insertion has a deleterious effect on parasite development, and does not confer a load (fitness cost) to the mosquito. The probability of finding such a site is likely to be low, so the minimally-acceptable should be determined by the efficacy of the DNA construct for the drive and anti-parasite phenotypes. This parameter is addressed more fully once the construct is integrated into its target mosquito host. Also, targeting of host factors essential for parasite development could be accomplished from a benign genomic insertion site by incorporating guide RNAs targeting the desired host factor in the gene-drive construct.

There is considerable debate about the significance of off-target effects (a direct mutational impact in the transgenic organism on a DNA sequence other than the target) in the broader application of CRISPR/Cas9-based technologies, but most of this is associated with efforts to modify specific genes in cells [32]. In this context, an off-target effect would fail to modify the intended gene and may cause a deleterious mutation as a result of gRNA-directed nuclease cleavage at a secondary genomic site. Off-target effects in population modification applications refer to the insertion of the drive-construct into a site in the genome other than that specified by the design of the gRNA or a non-specific mutation event at that site without integration. In the former case, the individual insect would still carry the anti-parasite effector genes and not be able to transmit malaria. Furthermore, it is not likely that this individual insect would be able to sustain drive at the off-target site as the gRNAs would still be specific for the original target site. It is possible that a drive construct could act as a trans-acting mutagen of secondary sites, and the impact would be manifest from the resulting phenotypes. If they are lethal, it should not present a significant problem because the insect carrying it would be removed from the population, but it is possible that other weaker phenotypes may become evident. Phenotypes such as these, and those that reduce mosquito fitness below crucial thresholds or allow them to transmit other pathogens can be monitored in early Phase 1, laboratory-based cages trials once the construct is integrated in the target species, and could be ‘go/no go’ decision points for a specific genomic target site and set of gRNAs.

Natural variation in the DNA of the drive component target site in the wild mosquito population could manifest as loci that are resistant to drive and others may be induced by the drive machinery [7,33,34]. Potential solutions are to use multiple gRNAs (more than one gRNA per target site locale) and multiple target sites in the genome [31]. Here the minimally-acceptable parameter is that these types of variations have no broad impact on the resistance phenotypes in the target mosquito populations. Non-target effects (direct or indirect impact on a species other than the target) can be mitigated by using guide RNAs complementary to DNA present only in the target species, and control DNA that is only functional in the target species (direct), and evaluating the context of an altered mosquitoes in the trial-site environment (indirect). A recent hazard formulation exercise found no basis for any significant indirect effects [10].

Modeling drive inheritance shows that it would be most efficient if it were active in both males and females, however, laboratory-based experiments show that the biology of early development of mosquitoes may favor having drive occur only in males [6,24,35]. This can be achieved using promoters that are functional in the pre-meiotic germ cells of males, although control DNA that allows Cas9 activity in female pre-meiotic germ cells also could be good. Alternatively, it may be possible to develop unstable and/or regulated forms of Cas9 that do not give rise to non-drive events in the egg.

A model of a strain-specific TPP

Many DECs face economic and expertise challenges that could prevent them from adopting population modification strategies. In these circumstances, close collaborations with discovery laboratories and funding agencies are needed. This model of interaction has the discovery laboratories making the transgene construct with both effector and drive elements, and being involved in the characterization, colonization and importation of the desired target mosquito species and strains. This work is followed by insertion of the population modification construct into the target mosquitoes, and the conducting of Phase 1 safety and efficacy trials prior to return of the engineered mosquitoes to the DEC of origin. All remaining Phase trials would be in the DEC. This approach has the benefit of making the technology accessible to some of the places where it is needed the most, but also poses significant challenges. Colonization and laboratory adaptation of wild-caught species can be problematic, although practical approaches for maintaining genetic
diversity and mating competitiveness have been developed and used [36]. Furthermore, biodiversity protection statutes may slow the export of critical mosquito species and reciprocally, the global regulatory environment for the movement of GMOs may represent a significant hurdle to returning the strains to the trial-site countries [11]. However, these challenges are not insurmountable, and researchers working in Mexico, Brazil and Burkina Faso obtained the necessary permits to import genetically-engineered mosquitoes [37–39].

The laboratory-developed strain would be introgressed over several generations into recently-colonized local mosquito populations prior to the completion of Phase trials in the DEC site. These are the mosquitoes that would be subject to the key parameter assessment of the TPP. This TPP is necessarily more complex and has multiple categories of parameters including effector efficacy, driver efficacy, fitness, safety, and production and release features (Table 4). This TPP also is appropriate for the DNA-only approach once the transgenes have been integrated into the target mosquitoes at the trial site.

Effector efficacy addresses the real-world malaria transmission dynamics facing a population modification strategy. There are few empirical studies that report the minimally infectious parasite inoculum needed to cause human malaria, but the conclusion appears to be that one or a small number of parasites is all that is needed to establish an infection [40]. These findings support the conclusion that the effector phenotypes should result in no parasites in mosquito salivary glands, and here the ideal and minimally-essential definitions are the same [41]. Modeling studies assume this level of efficiency [6].

The minimally-essential effector gene specificity for parasite targets overlaps that of the construct and would require an effect on either P. falciparum or P. vivax. The ideal proportion of the mosquito population carrying the effector gene needed to have an epidemiological impact on malaria transmission is 100%. However, in analogy with vaccine coverage, modeling supports the value of population modification approaches that reduce the basic reproductive rate ($R_0$) of malaria below one ($<1$) without having to achieve zero, but this is dependent on the mosquitoes carrying the effector genes having zero parasites in their salivary glands [6].

Criteria for the gene-drive components also reflect the real-world considerations of strain development and deployment. Ideal performance features would be a 100% introgression into the target wild mosquito populations within a single malaria transmission season (<1 year; 10–18 mosquito generations [7]). However, while it could be possible to achieve this ideal, the modeled levels of introgression and speed show favorable epidemiological impacts at 2–8 years [6,7].

Fitness criteria address male mating competitiveness and female fecundity. Previous applications of radiation-based sterile insect techniques (SIT) tolerated reductions of 80% of male competitiveness because this could be overcome by inundative release ratios of 10 treated insects for every wild insect (release ratio = 10:1), and similar effects were predicted from modeling genetically-engineered mosquito strains in which the release ratio are able to compensate for the aggregate fitness losses [42,43]. Furthermore, gene-drive systems are predicted to compensate for some reduction in male competitiveness. This level of male competitiveness also is predicted to be sufficient in mosquitoes if males can meet minimal parameters for local migration frequencies and distances [6]. Similar modeling shows that females also may be able to bear reductions in fecundity as large as 20% and still achieve introgression of the driven genes. Modeling of the impact of a construct that results in an effect on both males and females is needed once each has been determined, and we expect to develop robust strains that perform well beyond these parameter values.

Safety parameters pose several interesting challenges. These include mitigating known possible adverse effects, and having plans to respond to unanticipated events. Carefully planned and executed experiments during Phase trials should ease concerns about whether the transgenes and drive systems could broaden the vector competence or increase the vectorial capacity of the engineered mosquitoes for other pathogens. However, the need and capability to recall the mosquitoes from the field after release is still being debated [27,44]. We suggest that any early open-release trial should be conducted with the opportunity to execute an existing mitigation strategy if needed. For example, insecticide-based protocols could be used to remove engineered mosquitoes from the local environment. However, the practicality of this is questionable in regions where the local insects exhibit some level of insecticide resistance. Indeed, it may become impossible soon to find any mosquito populations anywhere in the malaria-endemic world that do not have some level of resistance to the most commonly-used insecticides. In these circumstances, it may be possible to take advantage of seasonal constraints on population sizes during which low density populations at the end of the rainy season may be easier to eliminate.

The recent enthusiasm and concerns over gene-drive technologies have promoted investigations of genetic and chemical-based control approaches that could mitigate unwanted outcomes of accidental or intentional release [45]. Significant resources have been made available to develop and test these approaches, but many remain at least as experimental as the original proposed drives. Whether they will be available, or necessary, as field trials start is still to be determined. Again, adding complexity to the genetic make-up increases the risk of unforeseen failures and we urge caution in deploying any so-called reversal-drive systems unless there is a compelling need.
Table 4. Draft framework for a target product profile of release strains: Partial list of key parameters and ideal and minimally essential performance features.

| Category                  | Parameter                              | Ideal                                                                 | Minimally Essential                                                                 |
|---------------------------|----------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Effector efficacy         | Efficacy (absence of sporozoites in salivary glands) | No parasites (zero prevalence, zero mean intensity of infection) in salivary glands of mosquitoes carrying single copy of single transgene | No parasites (as defined in ideal) in salivary glands of mosquitoes carrying single copy of more than one transgene (‘dual approach’) |
|                           | Parasite targets                       | All populations of all human malaria parasites                          | Regional populations of *Plasmodium falciparum* or *Plasmodium vivax*               |
|                           | Impact (malaria transmission blocking)  | Complete absence of malaria transmission in target area, no parasite-infected mosquitoes | To be determined                                                                     |
| Driver efficacy           | Efficacy (percent population carrying gene) | 100% introgression into target wild populations                        | ≥90%                                                                               |
|                           | Target Specificity                     |                                                                         | Same                                                                               |
|                           | Time to introgression                  | <1 year                                                                | 2–8 years                                                                           |
| Fitness                   | Male competitiveness                  | Equal or more than wild-type                                            | >20% of wild-type                                                                  |
|                           | Female fecundity                       | Equal or more than wild-type                                            | Same                                                                               |
| Safety                    | Safety (vector competence/vectorial capacity) | Strain does not promote disease/pathogen spread in target/non-target organisms; does not facilitate transmission of novel pathogens | Susceptible to elimination by insecticides, genetic or chemical recall             |
|                           | Safety (remediation)                   |                                                                         |                                                                                     |
| Production and Release    | Genetic                                | Maintained as homozygous strain                                         | Balanced heterozygous strain or outcross at every generation                       |
|                           | Formulation                            | Adult blood fed females                                                 | Adult males and females                                                            |
|                           | Shelf life                             | 3 weeks                                                                | 2–3 weeks                                                                           |
|                           | Duration of activity/dosing            | ~10 years                                                              | 2–8 years                                                                           |
|                           | Dosing regimen                         | One release regimen per product lifetime                                | Depends on migration rates and distance, local population structure, seasonal abundance |
|                           | Cost of treatment per breeding site    | Cost is well within the annual budget allocation for local vector control/public health | Cost does not exceed the standard budget allocation to the local vector control/public health during a typical malaria epidemic |
|                           | Preparation time                       | Short enough to meet the demand of treatment for large cities 1,000s to 100,000s of adult insects needed per treatment per site of target population | Will not exceed the demand for treatment                                              |
|                           | Batch preparation volume/size          |                                                                        |                                                                                     |
|                           | Susceptibility to loss of efficacy due to acquired resistance or loss of linkage | None                                                                    | Loss of linkage below critical threshold in ≥3 years                                |
|                           | Timing of release                      | Anytime during the year                                                 | Time that maximizes efficacy of introgression (seasonal)                           |
|                           | Release ratios                          | <1 transgenic:1 wild-type                                               | 10 transgenic:1 wild-type                                                           |
TPP parameters key to later stages of Phase testing include those relevant to scale-up, deployment and costs. One of the more interesting challenges will be defining the life stage of the mosquitoes to be released. Previous opinions were that any release should be done with males only because females can probe and feed and are a nuisance [46]. However, recent deployments of Wolbachia-infected strains of dengue vectors for population modification require releasing females as well because the symbiont is inherited maternally [47]. Adults mosquitoes were released in early sterile insect technique (SIT) trials because they have favorable weight-to-number ratios (no need to store or transport in water) and disperse immediately on release [42,48]. In addition, a release of a single blood-fed, fertilized female could be the equivalent of a delayed release of 100–300 mosquitoes [35].

While adult mosquitoes are more fragile than the sub-adult stages and may suffer losses during packaging and transport, releases of mixed populations of adult males and blood-fed females is likely the best approach. Adults can be expected to survive for 2–3 weeks in production facilities prior to release, but it is necessary to know the daily survival rates of the modification strains, and all factors considered, it would be best to release them as soon as the females have been mated and blood fed.

The ideal for the impact of a release would be that a single application (release) should show an effect for the time needed to ensure that there are no human reservoirs of the parasites that can serve as a source of infection of the mosquitoes. Minimally acceptable time frames would be those preventing the reintroduction of parasites into a malaria-free zone. Models support regimens of a single release at multiple sites in a target region to achieve quick introgression of transgenes and outpace drive-based generation of resistant genome target sites [6,7].

Modeling and other analyses support seasonal releases of the population modifications strain [5,6]. Releasing insects at the end of the dry season when wild target populations are small optimizes the release ratios and increases the probably of introgressing the effector genes more rapidly. Increases in mosquito abundance following the onset of rain would amplify the effects of the release strains. Release ratios will depend on the specific drive constructs and can be tested in Phase 1 and 2 cage trials.

TPP parameters for production are critical. Technologies may prove to be robust during the proof-of-principle development, and perform well when scaled up for a field trial. However, to be of practical use, it is necessary to rear the mosquitoes in sufficient numbers and in a time frame needed to meet the demands of a local control protocol. This demand could be for a few thousand mosquitoes for a small village up to hundreds of thousands needed for a complex urban environment. One of the predicted benefits of gene drive-based population modification approaches is that they should reduce the number of mosquitoes needed for releases [5]. It would be ideal if the production mosquitoes could be maintained as stable homozygous strains. This would minimize the amount of outcrossing needed just before production of large numbers for release. Stability is important so that strains do not lose their properties during production. This can be mitigated by scheduled testing of the strains in facilities. The currently available technologies are amenable to the easy remaking of the needed strains should they show any genetic breakdown during maintenance.

Concluding remarks

The phrase ‘never let the perfect become the enemy of the good’ applies to the transitional period we are experiencing for population modification strategies. There is a need to balance the search for a perfect strain with the demand for something that can be used in the field. TPPs are part of the process that guides the design and development of field-ready tools and will be used during the phase trial evaluations that are to be done prior to advancing a product to the field. We offer the comments here to stimulate the research and stakeholder communities to develop consensus frameworks for TPPs.

Acknowledgements

We thank the members of the James laboratory, Dr Ethan Bier (University of California, San Diego), and the many researchers worldwide who have provided input into the development of population modification technologies. Rhodell Valdez helped in the preparation of the manuscript. AAJ is a Donald Bren Professor at the University of California, Irvine.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

Research in the James laboratory is supported by awards from the Tata Institute for Genetics and Society, the Bill and Melinda Gates Foundation, the National Institutes of Health [grant number AI29746], the WM Keck Foundation and the University of California, Irvine Malaria Initiative.

References

[1] WHO. World Malaria Report, 2015. World Health Organization; 2016. ISBN: 978 92 4 1511711.
[2] Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–211.
[3] Barreaux P, Barreaux AMG, Sternberg ED, et al. Priorities for broadening the malaria vector control tool kit. Trends Parasitol. 2017 Oct;33(10):763–774.
[4] Adelman Z. Genetic control of malaria and dengue. Oxford: Elsevier Academic Press; 2015.
[5] Macias VM, James AA. Impact of genetic modification of vector populations on the malaria eradication agenda. In: Adelman Z, editor. Genetic control of malaria and dengue. Oxford: Elsevier Academic Press; 2015. p. 423–444.

[6] Eckhoff PA, Wenger EA, Godfray HC, et al. Impact of mosquito gene drive on malaria elimination in a computational model with explicit spatial and temporal dynamics. Proc Nat Acad Sci USA. 2016;114(2):E255–E264.

[7] Beaghton A, Hammond A, Nolan T, et al. Requirements for driving antipathogen effector genes into populations of disease vectors by Homing. Genetics. 2017 Apr;205(4):1587–1596.

[8] Curtis CF. Possible use of translocations to fix desirable genes in insect pest populations. Nature. 1968;218(5139):368–369.

[9] James AA, Pelouquin JJ. Engineering resistance to malaria parasite development in mosquitoes. In: Sherwin IW, editor. Malaria: parasite biology, pathogenesis and protection. Washington (DC): ASM Press; 1998. p. 63–69.

[10] Roberts A, Andrade PP, Okumufu F, et al. Results from THE WORKSHOP “Problem Formulation for the Use of Gene Drive in Mosquitoes”. Am J Trop Med Hyg 2017 Mar;96(3):530–533.

[11] WHO. Guidance framework for testing of genetically modified mosquitoes. Geneva: WHO/TDR Publications; 2014. ISBN 978 92 4 150748 6.

[12] Brown DM, James AA. Vector control – new approaches. In: Gubler DJ, Ooi EE, Vasudevan S, Farrar J, editors. Dengue and dengue hemorrhagic fever. 2nd ed. Wallingford: CAB International; 2014. p. 519–536.

[13] Hardy JL, Houk EJ, Kramer LD, et al. Intrinsic factors affecting vector competence of mosquitoes for arboviruses. Annu Rev Entomol. 1998;43:229–262.

[14] Smith DL, Battle KE, Hay SI, et al. Ross, Macdonald, and a theory for the dynamics and control of mosquito-transmitted pathogens. PLoS Pathog. 2012;8:e1002588.

[15] Meredith SE, James AA. Biotechnology as applied to vectors and vector control. Ann Parasitol Hum Comp. 1990;65(Suppl. I):113–118.

[16] Collins FH, James AA. Genetic modification of mosquitoes. Sci Med. 1996;3:52–61.

[17] Catteruccia F, Nolan T, Loukeris TG, Blass C, et al. Stable germline transformation of the malaria mosquito Anopheles stephensi. Nature. 2000;405(6789):959–962.

[18] Grossman GL, Rafferty CS, Clayton JR, et al. Germline transformation of the malaria vector, Anopheles gambiae, with the piggyBac transposable element. Insect Mol Biol. 2001;10:597–604.

[19] Corby-Harris V, et al. Activation of Akt signaling reduces the prevalence and intensity of malaria parasite infection and lifespan in Anopheles Stephensi mosquitoes. PLoS Pathog. 2010;6:e1000103.

[20] Isaacs AT, Jasinskaie N, Trettiaikov M, et al. Transgenic Anopheles stephensi co-expressing single-chain antibodies resist Plasmodium falciparum development. Proc Nat Acad Sci USA. 2012;109, E1922–E1930. PMID:22689959. PNAS PLUS; 109:11070–11071.

[21] Braig HR, Yan G. The spread of genetic constructs in natural insect populations. In: Letourneau DK, Burrows BE, editors. Genetically engineered organisms: assessing environmental and human health effects. Washington (DC): CRC Press; 2002. p. 251–314.

[22] James AA. Gene drive systems in mosquitoes: rules of the road. Trends Parasitol. 2005;21:64–67.

[23] Burt A. Site-specific selfish genes as tools for the control and genetic engineering of natural populations. Proc Biol Sci. 2003;270(1518):921–928.

[24] Gantz VM, Jasinskaie N, Tatarkoenva O, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito, Anopheles stephensi. Proc Nat Acad Sci USA. 2015;112(49):E6736–E6743.

[25] Hammond A, Galizi R, Kyrour K, et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol. 2015;34(1):78–83.

[26] Akbari OS, Bellon HJ, Bier E, et al. Biosafety. Safeguarding gene drive experiments in the laboratory. Science. 2015;349(6251):927–929.

[27] NASEM (National Academies of Sciences, Engineering, and Medicine). Gene drives on the horizon: advancing science, navigating uncertainty, and aligning research with public values. Washington (DC): The National Academies Press; 2016.

[28] Adelman Z, Akbari O, Bauer J, et al. Rules of the road for insect gene drive research and testing. Nat Biotechnol. 2017 Aug;35(8):716–718.

[29] Pike A, Dong Y, Dizaji NB, et al. Changes in the microbiota cause genetically modified Anopheles to spread in a population. Science. 2017 Sep 29;357(6358):1396–1399. doi:10.1126/science.aak9691. Epub 2017 Sep 28 PMID:28963254.

[30] Brown DM, Alphey LS, McKemey A, et al. Criteria for identifying and evaluating candidate sites for open-field trials of genetically engineered mosquitoes. Vector Borne Dis. 2014;14:291–299.

[31] Marshall JM, Buchman A, Sánchez CHM, et al. Overcoming evolved resistance to population-suppressing homing-based gene drives. Sci Rep. 2017;7:7377.

[32] Jiang F, Douhia JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017 May;46(1):505–529.

[33] Champer J, Reeves R, Oh SY, et al. Novel CRISPR/Cas9 gene drive constructs reveal insights into mechanisms of resistance allele formation and drive efficiency in genetically diverse populations. PLoS Genet. 2017 Jul 20;13(7):e1006796.

[34] Hammond AM, Kyrour K, Bruttini M, et al. The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito. PLoS Genet. 2017 Oct 4;13(10).e1007039. DOI:10.1371/journal.pgen.1007039.eCollection 2017 Oct. PMID:28976972.

[35] Ragsom JL, Scott TW. Impact of population age structure on Wolbachia transgene driver efficacy: ecologically complex factors and release of genetically modified mosquitoes. Insect Biochem Mol Biol. 2004;34:707–713.

[36] Wise de Valdez MR, Nimmo D, Betz J, et al. Genetic elimination of dengue vector mosquitoes. Proc Nat Acad Sci USA. 2011;108:4772–4775.

[37] Ramsey JM, Bond JG, Macotela ME, et al. A regulatory structure for working with genetically-modified mosquitoes: Lessons from Mexico. PLoS Negl Trop Dis. 2014;8(3).e2623.

[38] Carvalho DO, McKemey AR, Garziera L, et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl Trop Dis. 2015 Jul 2;9(7).e0003864.

[39] Target Malaria. http://targetmalaria.org/

[40] Ungureanu E, Killick-Kendrick R, Garnham PC, et al. Pre-patent periods of a tropical strain of Plasmodium vivax in Brazil by sustained release of transgenic male mosquitoes. Trans R Soc Trop Med Hyg. 1977;70:482–483.

[41] Jasinskaie N, Coleman J, Ashikyan A, et al. Genetic control of malaria parasite transmission: threshold levels for infection in an avian model system. Am J Trop Med Hyg. 2007;76:1072–1078.
[42] Klassen W, Curtis CF. History of the sterile insect technique. In: Dyck, VA et al., editors. The sterile insect technique: principles and practice in area-wide integrated pest management. Washington (DC): Springer Pew Initiative. Bugs in the system: issues in the science and regulation of genetically modified insects; 2004. p. 3–36.

[43] Robert MA, Legros M, Facchinelli L, et al. Mathematical models as aids for design and development of experiments: the case of transgenic mosquitoes. J Med Entomol. 2012 Nov;49(6):1177–1188.

[44] Vella MR, Gunning CE, Lloyd AL, Gould F evaluating strategies for reversing CRISPR-Cas9 gene drives. Sci Rep 2017;7:11038.

[45] DARPA. 2017. https://www.darpa.mil/news-events/2017-07-19

[46] Pew Trusts PC. Washington (DC): Springer Pew Initiative. Bugs in the system: issues in the science and regulation of genetically modified insects; 2004.

[47] Hoffmann AA, Montgomery BL, Popovic J, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011;476:454–457.

[48] Dame DA, Curtis CF, Benedict MQ, et al. Historical applications of induced sterilisation in field populations of mosquitoes. Malaria J. 2009;8(Suppl. 2):S2.

[49] Yoshida S, Matsuoka H, Luo E, et al. A single-chain antibody fragment specific for the Plasmodium berghei ookinete protein Pbs21 confers transmission blockade in the mosquito midgut. Mol Biochem Parasitol. 1999;104(2):195–204.

[50] Capurro K M, et al. Virus-expressed, recombinant single chain antibody blocks sporozoite infection of salivary glands in Plasmodium gallinaceum-infected Aedes aegypti. Am J Trop Med Hyg. 2000;62:427–433.

[51] Isaacs AT, Li F, Jasinskiene N, et al. Engineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi. PLoS Pathog. 2011;7(4):e1002017.

[52] Yoshida S, Ioka D, Matsuoka H, et al. Bacteria expressing single-chain immunotoxin inhibit malaria parasite development in mosquitoes. Mol Biochem Parasitol. 2001;113(1):89–96.

[53] Fang WG, Vega-Rodriguez J, Ghosh AK, et al. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science. 2011;331:1074–1077.

[54] Barreau C, Touray M, Oimenta P, et al. Plasmodium gallinaceum: sporozoite invasion of Aedes aegypti salivary glands is inhibited by anti-gland antibodies and by lectins. Exp Parasitol. 1993;81:332–343.

[55] Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature. 2002;417:452–455.

[56] Zieler H, Keister DB, Dvorak JA, et al. A snake venom phospholipase A2 blocks malaria parasite development in the mosquito midgut by inhibiting ookinete association with the midgut surface. J Exp Biol. 2001;204:4157–4167.

[57] Moreira LA, Ito J, Ghosh A, et al. Bee venom phospholipase inhibits malaria parasite development in transgenic mosquitoes. J Biol Chem. 2002;277:40839–40843.

[58] Tsai Y, Hayward RE, Langer RC, et al. Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut. Infect Immun. 2001;69:4048–4054.

[59] Gwadar RW, Kaslow D, Lee JY, et al. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect Immun. 1989;57:2628–2633.

[60] Shahabuddin M, Fields I, Bulet P, et al. Plasmodium gallinaceum: differential killing of some mosquito stages of the parasite by insect defensin. Exp. Parasitol. 1998;89:103–112.

[61] Violi J, Bulet P, Hoffmann JA, et al. Gambicin: a novel immune responsive antimicrobial peptide from the malaria vector Anopheles gambiae. Proc Nat Acad Sci USA. 2001;98:12630–12635.

[62] Moreira CK, Rodrigues FG, Ghosh A, et al. Effect of the antimicrobial peptide gomisin against different life stages of Plasmodium spp. Exp Parasitol. 2007;116:346–353.

[63] Rodríguez MC, Zamudio F, Torres JA, et al. Effect of a cecropin-like synthetic peptide (Shiva-3) on the sporogonic development of Plasmodium berghei. Exp Parasitol. 1995;80:596–604.

[64] Luckhart S, Vodovoz Y, Cui L, et al. The mosquito Anopheles stephensi limits malaria parasite development with inducible synthesis of nitric oxide. Proc Nat Acad Sci USA. 1998;95:5700–5705.

[65] Yoshida S, Shimada Y, Kondoh D, et al. Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic mosquitoes impairs malaria parasite development. PLoS Pathog. 2007;3:e192.

[66] Arirghi RB, Ebikeme C, Jiang Y, et al. Cell-Penetrating Peptide TP10 Shows Broad-Spectrum Activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrob Agents Chemother. 2008;52:3414–3417.

[67] Gao B, Rodriguez Mdel C, Lanz-Mendoza H, et al. AdiLP, a bacterial defensin-like peptide, exhibits anti-Plasmodium activity. Biochem Biophys Res Commun. 2009;378:393–398.

[68] Gao B, Xu J, Rodriguez Mdel C, et al. Characterization of two linear cationic antimalarial peptides in the scorpion Mesobuthus eupeus. Biochimie. 2010;92:330–339.

[69] Conde R, Zamudio FZ, Rodriguez MH, et al. Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom. FEBS Lett. 2000;471:165–168.

[70] Carballar-Lejarazu R, Rodríguez MH, de la Cruz Hernández-Hernández F, et al. Recombinant scorpine: a multifunctional antimicrobial peptide with activity against different pathogens. Cell Mol Life Sci. 2008;65(19):3081–3092.

[71] Zhang G, Niu G, Franca CM, et al. Anopheles midgut FREP mediates Plasmodium invasion. J Biol Chem. 2015;290(27):16490–16501.

[72] Dong Y, Das S, Cirimotich C, et al. Engineered anopheline immunity to Plasmodium infection. PLoS Pathog. 2011;7:e1002458.

[73] Abraham EG, Donnelly-Doman M, Fujioka H, et al. Driving midgut-specific expression and secretion of a foreign protein in transgenic mosquitoes with AgAper1 regulatory elements. Insect Mol Biol. 2005 Jun;14(3):271–279.

[74] Nolan T, Petris E, Muller HM, et al. Analysis of two novel midgut-specific promoters driving transgene expression in Anopheles stephensi mosquitoes. PLoS ONE. 2011;6(2):e16471.

[75] Chen XG, Marinotti O, Whitman L, et al. The Anopheles gambiae vitellogenin gene (VGT2) promoter directs persistent accumulation of a reporter gene product in transgenic Anopheles stephensi following multiple bloodmeals. Am J Trop Med Hyg. 2007;76:1118–1124.

[76] Yoshida S, Watanabe Y. Robust salivary gland-specific transgene expression in Anopheles stephensi mosquitoes. Insect Mol Biol. 2006;15:403–410.

[77] Lobardo F, Nolan T, Lyczek G, et al. An Anopheles gambiae salivary gland promoter analysis in Drosophila melanogaster and Anopheles stephensi. Insect Mol Biol. 2005;14:207–216.